Drugs for Life: How Pharmaceutical Companies Define Our Health
Every year the average number of prescriptions purchased by Americans increases, as do healthcare expenditures, which are projected to reach one-fifth of the U.S. gross domestic product by 2020. In Drugs for Life, Joseph Dumit considers how our burgeoning consumption of medicine and cost of healthcare not only came to be, but also came to be taken for granted. For several years, Dumit attended pharmaceutical industry conferences; spoke with marketers, researchers, doctors, and patients; and surveyed the industry's literature regarding strategies to expand markets for prescription drugs. He concluded that underlying the continual growth in medications, disease categories, costs, and insecurity is a relatively new perception of ourselves as inherently ill and in need of chronic treatment. This perception is based on clinical trials that we have largely outsourced to pharmaceutical companies. Those companies in turn see clinical trials as investments and measure the value of those investments by the size of the market and profits that they will create. They only ask questions for which the answer is more medicine. Drugs for Life challenges our understanding of health, risks, facts, and clinical trials, the very concepts used by pharmaceutical companies to grow markets to the point where almost no one can imagine a life without prescription drugs.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Responding to Facts
Pharmaceutical Witnessing and Direct to Consumer Advertising
Having to Grow Medicine
Mass Health Illness Is a Line You Cross
Moving the Lines Deciding on Thresholds
Other editions - View all
advertising awareness Bartfai and Lees become biomarkers biomedical blockbuster drugs breast cancer campaigns ceutical chapter cholesterol levels chronic clinical trials clinicians commercial consumers Crestor David Healy defined depression designed diabetes diagnoses doctors dtc advertisement Dumit expert patient Express Scripts facts fosamax future groups Grove grow growth guidelines HbA1c healthcare heart attack heart disease high cholesterol Ibid illness increase indicated investment joke lifestyle lives logic mass health measure medicine ment metabolic syndrome notion one’s percent person pharma companies pharmaceutical companies pharmaceutical industry pharmaceutical marketing physicians pill population possible potential prescribed prescriptions prevent problem profit prostate cancer psA test public health question reduce result risk factors risk reduction scientific screening sense shift side effects social statins statistical strategy studies surplus health symptoms talk threshold tion treat treatment understand women worry Zoloft